Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-02-07 00:00:00 ET · period of report 2023-02-06 · accession 0000899243-23-004238 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-07 | 2023-02-06 | VRDN | Myers Scott Dunseth | CEO, Dir | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
| D | 2023-02-07 | 2023-02-06 | VRDN | Myers Scott Dunseth | CEO, Dir | A - Grant | $0.00 | +1.00M | 1.00M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | A | A | 250,000 | $0.00 | 250,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-06 | A | A | 1,000,000 | $0.00 | 1,000,000 | D | $35.80 · — to 2033-02-06 | 1,000,000 Common Stock | (F2) The option vests 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |